lncb74
·Code: LNCB74
lncb74: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| NextCure, Inc. (NXTC) | Phase 1 |
Clinical Trials (1)
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors
Frequently asked questions
Who is developing lncb74?
lncb74 is being developed by NextCure, Inc..
How many clinical trials involve lncb74?
BioSniper tracks 1 clinical trial involving lncb74.
Get deeper analysis on lncb74
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis